Zhejiang East-Asia Pharmaceutical (605177.SH) issues a profit warning, expecting a net loss of 95 to 115 million yuan in the fiscal year 2024.

Zhejiang East-Asia Pharmaceutical (605177.SH) released its performance forecast for 2024, projecting a net loss attributable to shareholders of the listed company ranging from 95 million yuan to 115 million yuan. It is expected that the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, will be between 90 million yuan and 110 million yuan in 2024.